Risperidone in the treatment of children and adolescents with schizophrenia: A retrospective study
Risperidone in the treatment of children and adolescents with schizophrenia: A retrospective study
复制标题
DOI：
10.1089/cap.1996.6.251
复制
发表时间：
1996-12-01
影响因子：
1.9
通讯作者：
Schulz, SC
中科院分区：
文献类型：
--
作者：
Grcevich, SJ;Findling, RL;Schulz, SC
利培酮是一种新的非典型抗精神病药物，据报道，与传统的精神安定药相比，它在精神分裂症成人患者中的锥体外系副作用（EPS）较少。本研究评估了利培酮在16名儿童和青少年（年龄9 - 20岁，平均14.9岁）中的安全性和有效性，这些儿童和青少年临床诊断为精神障碍：13名患者符合DSM-III-R精神分裂症标准，2名符合情感障碍标准，1名患有精神分裂症样障碍。16名患者中有11名曾接受过不成功的精神抑制剂试验。由患者的儿童和青少年精神科医生审查患者病历，以了解诊断、临床变化和不良事件。使用简明精神病评定量表（BPRS）和临床总体印象量表（CGI）回顾性评估临床反应。随着利培酮剂量的逐渐滴定，发现最佳临床反应为平均日剂量5.93 mg（范围2 - 10 mg）。16例患者中除1例外均对利培酮治疗有充分的临床反应。CGI（p <0.0001）、BPRS总评分（p <0.0001）和BPRS阴性症状评分（p <0.001）均有统计学显著性改善。一般而言，仅发生轻度药物诱导的副作用，似乎在改善该年龄组的精神分裂症症状方面安全有效。据推测，逐步滴定利培酮是实现相对较低的EPS率的关键。
Risperidone is a newly available atypical antipsychotic agent that has been reported to be associated with fewer extrapyramidal side effects (EPS) than conventional neuroleptics in adults with schizophrenia. This study assessed the safety and efficacy of risperidone in 16 children and adolescents (aged 9-20 years, mean 14.9 years) who were clinically diagnosed with psychotic disorders: 13 patients met DSM-III-R criteria for schizophrenia, 2 met criteria for schizoaffective disorder, and 1 had schizophreniform disorder. Eleven of the 16 patients had previous unsuccessful neuroleptic trials. Patient charts were reviewed by the patients' child and adolescent psychiatrist for diagnoses, clinical changes, and adverse events. Clinical response was assessed retrospectively using the Brief Psychiatric Rating Scale (BPRS) and the Clinical Global Impression (CGI) scale. With the risperidone dose titrated gradually, an optimal clinical response was found at a mean daily risperidone dose of 5.93 mg (range 2-10 mg). All but one of the 16 patients had an adequate clinical response to risperidone therapy. Statistically significant improvements were found in the CGI (p < 0.0001), the BPRS Total Score (p < 0.0001), and the BPRS Negative Symptom Score (p < 0.001). In general, only mild drug-induced side effects were experienced, appeared to be safe and effective in ameliorating symptoms of schizophrenia in this age group. It is speculated that the gradual titration of risperidone was crucial in achieving a relatively low rate of EPS.